Dr. Courtright is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7777 Forest LN
Bldg D Suite 400
Dallas, TX 75230Phone+1 972-566-7790Fax+1 972-566-5819
Education & Training
University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 1999 - 2001- University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 1996 - 1999
- University of Oklahoma College of MedicineClass of 1996
Certifications & Licensure
TX State Medical License 2003 - 2026
MO State Medical License 2001 - 2004
OK State Medical License 1997 - 2001
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Start of enrollment: 2019 Oct 15
Roles: Principal Investigator
Publications & Presentations
PubMed
- 1 citationsOUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.Yuliya Linhares, Cesar O Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris
Blood Advances. 2024-12-10 - 2 citationsLenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNO...Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, Matthew H Taylor, Christopher Di Simone
European Urology. 2024-11-01 - 101 citationsLenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.Chung-Han Lee, Amishi Yogesh Shah, Drew W. Rasco, Arpit Rao, Matthew H. Taylor
The Lancet. Oncology. 2021-07-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
